Sam Brusco, Associate Editor04.30.24
BioSig Technologies has appointed Anthony Amato as its new CEO, effective immediately. Amato will also join the company’s board of directors, which is currently being assembled.
Earlier this month, BioSig announced that Bridge Associates International Pharmaceutical Consulting (BAIPC), led by Amato, had been engaged. The corporate action, according to BioSig, was a natural progression as it realizes meaningful progress toward the goals of resorting and creating lasting shareholder value.
“Approximately 2 months ago, I took the initiative to review, analyze, and address the urgent issues that had the potential to negatively impact the company’s future,” Amato told the press. “Since then, important and material progress has been realized on multiple fronts, and I have accepted this new position to accelerate the implementation of the comprehensive turnaround strategy. The Company believes that there is substantial value to be unlocked through its current assets including its core product line, PURE EP. We will continue to add the appropriate team to reach our goals. I wish to thank our many loyal shareholders and reiterate my unwavering commitment to both restore and create shareholder value.”
BioSig’s PURE EP is an FDA 510(k)-cleared non-invasive device for real-time signal visualization. It lets physicians perform targeted cardiac ablation procedures with better procedural efficiency and efficacy, according to the company.
Amato is a business leader and entrepreneurial thinker—in March 2017, he founded InQuest Science then acquired Bridge Associates International Pharmaceutical Consulting in March 2020.
He’s also the former director of sales for Mesa Labs, a company specializing in quality control products and services to safety and efficacy of equipment used in hospitals, pharmaceutical, medical device manufacturers, blood banks, laboratories, pharmacies, and industrial facilities.
In July 1999, he founded Amega Scientific, growing the company from a startup to a worldwide industry leader. He managed a staff in North America, establishing R&D, production, logistics, and sales. Clients spanned pharmaceutical, biotech, hospitals, government facilities, and research universities.
Amega Scientific focused on the environmental monitoring system industry. It was an ISO 17025 corporation instituting GxP requirements and was acquired by Mesa Labs in November 2013.
Earlier this month, BioSig announced that Bridge Associates International Pharmaceutical Consulting (BAIPC), led by Amato, had been engaged. The corporate action, according to BioSig, was a natural progression as it realizes meaningful progress toward the goals of resorting and creating lasting shareholder value.
“Approximately 2 months ago, I took the initiative to review, analyze, and address the urgent issues that had the potential to negatively impact the company’s future,” Amato told the press. “Since then, important and material progress has been realized on multiple fronts, and I have accepted this new position to accelerate the implementation of the comprehensive turnaround strategy. The Company believes that there is substantial value to be unlocked through its current assets including its core product line, PURE EP. We will continue to add the appropriate team to reach our goals. I wish to thank our many loyal shareholders and reiterate my unwavering commitment to both restore and create shareholder value.”
BioSig’s PURE EP is an FDA 510(k)-cleared non-invasive device for real-time signal visualization. It lets physicians perform targeted cardiac ablation procedures with better procedural efficiency and efficacy, according to the company.
Amato is a business leader and entrepreneurial thinker—in March 2017, he founded InQuest Science then acquired Bridge Associates International Pharmaceutical Consulting in March 2020.
He’s also the former director of sales for Mesa Labs, a company specializing in quality control products and services to safety and efficacy of equipment used in hospitals, pharmaceutical, medical device manufacturers, blood banks, laboratories, pharmacies, and industrial facilities.
In July 1999, he founded Amega Scientific, growing the company from a startup to a worldwide industry leader. He managed a staff in North America, establishing R&D, production, logistics, and sales. Clients spanned pharmaceutical, biotech, hospitals, government facilities, and research universities.
Amega Scientific focused on the environmental monitoring system industry. It was an ISO 17025 corporation instituting GxP requirements and was acquired by Mesa Labs in November 2013.